LPCAT1 (E4V4B) Rabbit mAb

LPCAT1 (lysophosphatidylcholine acyltransferase 1), an enzyme that functions in phospholipid metabolism and remodeling, has been reported to be highly expressed and to play a tumor-promoting role in multiple human cancers. Overexpression of LPCAT1 is linked to poor prognosis in breast cancer and hepatocellular carcinoma (HCC) (1,2). In cervical cancer, knockdown of LPCAT1 reduces proliferation, migration, and invasion of cancer cells, and LPCAT1 deletion reduces tumor growth and metastasis in mice through Jak2/Stat3 signaling (3). In endometrial cancer, LPCAT1 enhances stemness and metastasis through TGF-β signaling (4). In non-small cell lung cancer (NSCLC), LPCAT1 upregulates EGFR/PI3K/Akt signaling, promoting resistance to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKI) (5). Due to its high expression in cancer, as well as its role in tumor promotion and drug resistance, LPCAT1 is a potential therapeutic target and prognostic biomarker. 1.Lebok, P. et al. (2019) Aging (Albany NY) 11, 7796-7804. 2.He, R.Q. et al. (2021) Cancer Cell Int 21, 442. 3.Gao, F. et al. (2022) Exp Cell Res 421, 113360. 4.Zhao, T. et al. (2022) Acta Biochim Biophys Sin (Shanghai) 54, 1-13. 5.Ding, J. et al. (2022) J Cancer 13, 1837-1847.